Investornewsbreaks Volitionrx Limited (NYSE American: VNRX) Completes Automation Validation For Nu.Q Vet Cancer Test In Japan

(MENAFN- Investor Brand Network) VolitionRx (NYSE American: VNRX) announced the successful validation and verification of the chemiluminescent immunoassay version of its Nu.Q Vet Cancer Test with Fujifilm Vet Systems Co. Ltd in Japan, enabling full automation in central laboratories through the IDS i10 automated analyzer platform. The company said the transition from manual plates to automated processing is expected to support faster turnaround and higher throughput as demand grows, with more than 1,700 veterinary hospitals in Japan already registered to use the test. Volition highlighted Japan's approximately seven million pet dogs and noted the automated platform aligns with the same system used for its human Nu.Q Cancer, Nu.Q NETs and Nu.Q Discover products, underscoring cross-platform synergy.

To view the full press release, visit:

About Volition

About Volition: Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.

Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.

Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.

The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.

For further information, visit the company's website at

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio IBN: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ; (2) article and editorial syndication to 5,000+ outlets ; (3) enhanced press release enhancement to ensure maximum impact ; (4) social media distribution via IBN to millions of social media followers ; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-

InvestorWire
Austin, Texas

512.354.7000 Office
[email protected]

InvestorWire is powered by IBN

MENAFN06032026000224011066ID1110828399